The Goldman Sachs Group Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $57.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective cut by The Goldman Sachs Group from $66.00 to $57.00 in a report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock. Other equities research analysts also recently issued reports about the company. StockNews.com upgraded CRISPR Therapeutics to a “sell” […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective cut by The Goldman Sachs Group from $66.00 to $57.00 in a report released on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock. Other equities research analysts also recently issued reports about the company. StockNews.com upgraded CRISPR Therapeutics to a “sell” […]
